Results 1 to 10 of about 61,853 (265)

Familial Parkinson’s Disease/Parkinsonism [PDF]

open access: yesBioMed Research International, 2015
Parkinson's disease (PD) is the second most common neurodegenerative disorder characterized by parkinsonism (bradykinesia, resting tremor, rigidity, and postural instability) with good response to L-dopa. Although the majority of PD patients are sporadic, it is now clear that genetic factors contribute to the pathogenesis of PD.
Hiroyuki Tomiyama   +3 more
openaire   +2 more sources

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease

open access: yesJournal of Neuroinflammation, 2023
Discoidin Domain Receptor (DDR)-1 is activated by collagen. Nilotinib is a tyrosine kinase inhibitor that is FDA-approved for leukemia and potently inhibits DDR-1.
Max Stevenson   +7 more
doaj   +1 more source

Clinical neurophysiology of Parkinson’s disease and parkinsonism [PDF]

open access: yesClinical Neurophysiology Practice, 2022
This review is part of the series on the clinical neurophysiology of movement disorders. It focuses on Parkinson's disease and parkinsonism. The topics covered include the pathophysiology of tremor, rigidity and bradykinesia, balance and gait disturbance and myoclonus in Parkinson's disease.
Chen, Robert   +16 more
openaire   +4 more sources

Viral Parkinsonism: An underdiagnosed neurological complication of Dengue virus infection

open access: yesPLoS Neglected Tropical Diseases, 2022
Dengue virus (DENV) is a flavivirus that is a significant cause of human disease costing billions of dollars per year in medical and mosquito control costs. It is estimated that up to 20% of DENV infections affect the brain.
Hannah K. Hopkins   +2 more
doaj   +2 more sources

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

open access: yesAlzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for ...
Fernando L. Pagan   +8 more
doaj   +1 more source

Progress on diagnosis and treatment of functional parkinsonism

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2023
Functional parkinsonism (FP) is a disorder caused by psychological factors rather than neurodegeneration. Functional parkinsonism has a great influence on patients' quality of life and daily function. However, due to overlapping with some of the symptoms
HUANG Pei, WANG Gang
doaj   +1 more source

Sleep Disorders in Early-Onset Parkinsonism: A Population-Based Study

open access: yesJournal of Parkinson’s Disease, 2023
Background: Sleep disturbances are common in parkinsonian disorders; however, whether sleep disorders affect individuals with early-onset parkinsonism and whether they differ from individuals with typical-onset parkinsonism is unknown.
Stuart J. McCarter   +7 more
doaj   +1 more source

Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)

open access: yesJournal of Parkinson’s Disease, 2021
Background: Early-onset Parkinson’s disease (EOPD), occurring between ages 40 and 55, carries social, societal, and personal consequences and may progress, with fewer comorbidities than typical, later-onset disease.
Emanuele Camerucci   +9 more
doaj   +1 more source

Decreased N-TAF1 expression in X-linked dystonia-parkinsonism patient-specific neural stem cells

open access: yesDisease Models & Mechanisms, 2016
X-linked dystonia-parkinsonism (XDP) is a hereditary neurodegenerative disorder involving a progressive loss of striatal medium spiny neurons. The mechanisms underlying neurodegeneration are not known, in part because there have been few cellular models ...
Naoto Ito   +12 more
doaj   +1 more source

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration

open access: yesDrugs in R&D, 2019
Background and objectives Inhibition of Abelson (Abl) tyrosine kinase as a therapeutic target has been gaining attention in neurodegeneration. Post-mortem Alzheimer’s and Parkinson’s disease brains show that the levels of several other tyrosine kinases ...
Alan J. Fowler   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy